Cargando…

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

BACKGROUND: The mesenchymal–epithelial transition (MET) pathway is frequently altered in tumours. The purpose of our study was to determine the prognostic value of tumour MET expression levels in patients with triple-negative breast cancer (TNBC), in order to strengthen the rationale for targeted th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zagouri, F, Bago-Horvath, Z, Rössler, F, Brandstetter, A, Bartsch, R, Papadimitriou, C A, Dimitrakakis, C, Tsigginou, A, Papaspyrou, I, Giannos, A, Dimopoulos, M-A, Filipits, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619063/
https://www.ncbi.nlm.nih.gov/pubmed/23422757
http://dx.doi.org/10.1038/bjc.2013.31
_version_ 1782265457768660992
author Zagouri, F
Bago-Horvath, Z
Rössler, F
Brandstetter, A
Bartsch, R
Papadimitriou, C A
Dimitrakakis, C
Tsigginou, A
Papaspyrou, I
Giannos, A
Dimopoulos, M-A
Filipits, M
author_facet Zagouri, F
Bago-Horvath, Z
Rössler, F
Brandstetter, A
Bartsch, R
Papadimitriou, C A
Dimitrakakis, C
Tsigginou, A
Papaspyrou, I
Giannos, A
Dimopoulos, M-A
Filipits, M
author_sort Zagouri, F
collection PubMed
description BACKGROUND: The mesenchymal–epithelial transition (MET) pathway is frequently altered in tumours. The purpose of our study was to determine the prognostic value of tumour MET expression levels in patients with triple-negative breast cancer (TNBC), in order to strengthen the rationale for targeted therapy of TNBC using MET inhibitors. METHODS: We determined expression of MET in formalin-fixed paraffin-embedded surgical specimens of TNBC by immunohistochemistry. Recurrence-free and overall survival was analysed with Cox models adjusted for clinical and pathological factors. RESULTS: Immunostaining for MET was classified as high in 89 of 170 (52%) tumours. MET expression was more frequently observed in G3 carcinomas (P=0.02) but was not significantly associated to any of the other clinical or pathological parameters. High MET expression predicted shorter survival of the patients. Multivariate Cox proportional hazards regression analyses identified MET to be an independent prognostic factor for recurrence (adjusted hazard ratio (HR) for recurrence 3.43; 95% confidence interval (CI) 1.65–7.12; P=0.001) and death (adjusted HR for death 3.74; 95% CI 1.65–8.46; P=0.002). CONCLUSION: These results provide further evidence that the MET pathway could be exploited as a target for TNBC.
format Online
Article
Text
id pubmed-3619063
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36190632014-03-19 High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer Zagouri, F Bago-Horvath, Z Rössler, F Brandstetter, A Bartsch, R Papadimitriou, C A Dimitrakakis, C Tsigginou, A Papaspyrou, I Giannos, A Dimopoulos, M-A Filipits, M Br J Cancer Molecular Diagnostics BACKGROUND: The mesenchymal–epithelial transition (MET) pathway is frequently altered in tumours. The purpose of our study was to determine the prognostic value of tumour MET expression levels in patients with triple-negative breast cancer (TNBC), in order to strengthen the rationale for targeted therapy of TNBC using MET inhibitors. METHODS: We determined expression of MET in formalin-fixed paraffin-embedded surgical specimens of TNBC by immunohistochemistry. Recurrence-free and overall survival was analysed with Cox models adjusted for clinical and pathological factors. RESULTS: Immunostaining for MET was classified as high in 89 of 170 (52%) tumours. MET expression was more frequently observed in G3 carcinomas (P=0.02) but was not significantly associated to any of the other clinical or pathological parameters. High MET expression predicted shorter survival of the patients. Multivariate Cox proportional hazards regression analyses identified MET to be an independent prognostic factor for recurrence (adjusted hazard ratio (HR) for recurrence 3.43; 95% confidence interval (CI) 1.65–7.12; P=0.001) and death (adjusted HR for death 3.74; 95% CI 1.65–8.46; P=0.002). CONCLUSION: These results provide further evidence that the MET pathway could be exploited as a target for TNBC. Nature Publishing Group 2013-03-19 2013-02-19 /pmc/articles/PMC3619063/ /pubmed/23422757 http://dx.doi.org/10.1038/bjc.2013.31 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Zagouri, F
Bago-Horvath, Z
Rössler, F
Brandstetter, A
Bartsch, R
Papadimitriou, C A
Dimitrakakis, C
Tsigginou, A
Papaspyrou, I
Giannos, A
Dimopoulos, M-A
Filipits, M
High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
title High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
title_full High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
title_fullStr High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
title_full_unstemmed High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
title_short High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
title_sort high met expression is an adverse prognostic factor in patients with triple-negative breast cancer
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619063/
https://www.ncbi.nlm.nih.gov/pubmed/23422757
http://dx.doi.org/10.1038/bjc.2013.31
work_keys_str_mv AT zagourif highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT bagohorvathz highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT rosslerf highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT brandstettera highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT bartschr highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT papadimitriouca highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT dimitrakakisc highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT tsigginoua highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT papaspyroui highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT giannosa highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT dimopoulosma highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer
AT filipitsm highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer